Top Tweets for #COMP360

over 4 years ago

Positive data on #COMP360 keep coming – latest exploratory results show potential as adjunctive therapy, building on Ph2b monotherapy data last month. Excited to see how the Ph3 will shape up. Proud that @COMPASSPathway is part of the @atai_life journey https://t.co/MoJEiTscMl

1

12

1

0

over 4 years ago

More data from @COMPASSPathway show potential of #COMP360 as adjunctive therapy, building on results from prior Phase 2b monotherapy trial. Important for patients with treatment-resistant #depression & key insights towards the upcoming Ph3 trial design https://t.co/iqBvFiCpOk

2

16

6

0

over 4 years ago

Further reasons to believe in @COMPASSPathway & #COMP360 – new post-hoc analyses show further improvements critical to patients with treatment-resistant #depression. This week we increased our ownership position. These latest data renew our confidence! https://t.co/8PmsxxwGrM

1

3

0

over 4 years ago

Just in: post-hoc analyses of #COMP360 P2b in TRD by @COMPASSPathway show further improvements in key areas central to #patient recovery: #anxiety, self-reported #depression, positive & negative affect, functioning & quality of life. Congrats again to all! https://t.co/kG1O2bU5kX

0

23

5

0

over 4 years ago

A little history of #psilocybin to put today’s news, our increased stake in @COMPASSPathway in context. #COMP360 #psychedelics #mentalhealth

ataibeckley's tweet photo. A little history of #psilocybin to put today’s news, our increased stake in @COMPASSPathway in context.

#COMP360 #psychedelics #mentalhealth https://t.co/mMuEt9Eucp

1

34

7

4

0

Mr_Shares_Expert

@MrShare_expert

over 4 years ago

$ATAI a #psychedlics company listed on #NASDAQ worth billions increases its stake in $CMPS (another #psychedelics monster on #nasdaq) to 20.8% demonstrating confidence in their #COMP360 phase2b results #ASX $EMD with a strong future... you dont want to miss this train imo DYOR

over 4 years ago

UPDATE: atai increases ownership in @COMPASSPathway to 20.8%. Demonstrating our strong confidence in COMPASS, its milestone P2b #COMP360 #psilocybin data & its future in #psychedelics #mentalhealth #innovation See: https://t.co/SLFTonrxej

1

47

9

3

0

7

1

0

over 4 years ago

The recent #COMP360 #psilocybin #depression data was game-changing. So we’re increasing our stake in @COMPASSPathway to 20.8% in a firm show of confidence. We invested when they started & believe in their strong future in #mentalhealth See: https://t.co/7XhHBdT9aI

Srinivas G. Rao @SriniGRao

over 4 years ago

UPDATE: atai increases ownership in @COMPASSPathway to 20.8%. Demonstrating our strong confidence in COMPASS, its milestone P2b #COMP360 #psilocybin data & its future in #psychedelics #mentalhealth #innovation See: https://t.co/SLFTonrxej

1

47

9

3

0

22

5

0

over 4 years ago

We’re so impressed by the @COMPASSPathway #COMP360 P2b #psilocybin TRD data that we’re raising our stake to 20.8%. Proud to make such a public show of confidence in the company, data, clinical programs & its future in #mentalhealth. See: https://t.co/tzUp3VvCRx

over 4 years ago

UPDATE: atai increases ownership in @COMPASSPathway to 20.8%. Demonstrating our strong confidence in COMPASS, its milestone P2b #COMP360 #psilocybin data & its future in #psychedelics #mentalhealth #innovation See: https://t.co/SLFTonrxej

1

47

9

3

0

8

1

0

The Momentum Letter @MomentumLetter

over 4 years ago

UPDATE: atai increases ownership in @COMPASSPathway to 20.8%. Demonstrating our strong confidence in COMPASS, its milestone P2b #COMP360 #psilocybin data & its future in #psychedelics #mentalhealth #innovation See: https://t.co/SLFTonrxej

1

47

9

3

0

over 4 years ago

Psychedelic Drug Shows Promise in Treatment-Resistant Depression $CMPS $DELC $DELCF #COMP360 https://t.co/iMD9y5CrvX

0

1

0

Srinivas G. Rao @SriniGRao

over 4 years ago

Just in – #COMP360 #psilocybin P2b shows rapid & durable benefits in TRD. Major addition to the evidence for #psychedelics in #mentalhealth. Congrats to @LarsWilde, Ekaterina Malievskaia, George Goldsmith & all at @COMPASSPathway. My thoughts:

1

7

0

over 4 years ago

Following today’s important #psilocybin readout of @COMPASSPathway’s #COMP360 P2b in treatment-resistant depression, hear our Co-Founder & CEO, @FloBrand & Co-Founder & CSO, @SriniGRao give their thoughts on the data & implications. #psychedelics #mentalhealth

0

14

1

0

over 4 years ago

Important news for patients: #COMP360 #psilocybin P2b shows rapid & durable improvements in TRD. Congrats to @LarsWilde, Ekaterina Malievskaia, George Goldsmith & team, @COMPASSPathway & @atai_life. Hear my thoughts:

3

35

8

1

0